Skip to main content

Table 8 Summary of published data from tumor MMR analysis from suspected Latin America LS families

From: A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America

Latin America published data Number of families Number of individuals Clinical criteria MMR deficient (%) MMR non-deficient (%) Loss IHC   MSI
AMSII Revised Bethesda Other criteria MLH1 (%) PMS2 (%) MSH2 (%) MSH6 (%) PMS1 or MSH3* (%) MSI-H (%) MSS (%)
Medellin, Colombia [16] 41 41 4 27 10 14 (34.1) 27 (65.9) na na na na na 14 (34.1) 27 (65.9)
Rosario Santa Fe, Argentina [14] 1 3 1 na na 1 (33.3) 2 (66.7) na na na na na 1 (33.3) 2 (66.7)
Sao Paulo, Brazil [15] 106 106 na na na 14 (13.2) 92 (86.8) na na na na na 14 (13.2) 91 (85.9)
Buenos Aires, Argentina [18] 41 40 16 0 25 18 (45) 22 (55) 12 (30) na 7 (17.5) na na 13 (32.5) 17 (42.5)
Minas Gerais, Brazil [22] 66 66 8 15 43 15 (22.7) 51 (77.3) na na na na na 15 (22.7) 51 (77.3)
San Juan, Puerto Rico [21] 164 164 na na na 7 (4.3) 157 (95.7) 1 (0.06) na 6 (3.7) na na 1 (0.6) na
Lima, Peru [24] 90 90 na na na 35 (38.9) 55 (61.1) 23 (25.6) 18 (20) 4 (4.4) 2 (2.2) na 26 (28.9) 64 (71.1)
Rio Grande do Sul, Brazil [25] 212 197 22 100 0 42 (21.3) 155 (78.7) na na na na na 42 (21.4) 155 (78.7)
Mexico City, Mexico [27] 10 6 0 5 1 2 (33.3) 4 (66.7) 2 (33.3) na 0 na na na na
Minas Gerais, Brazil [28] 77 77 10 17 10 16 (20.8) 61 (79.2) na na na na na 16 (20.8) 61 (79.2)
Santiago, Chile [31] 35 35 19 16 na 21 (60) 14 (40) 21 (60) 0 6 (17.1) 4 (11.4) na 28 (80) 7 (20)
Lambayeque, Peru [35] 5 3 5 0 na 1 (33.3) 2 (66.7) 1 (33.3) 1 (33.3) 0 0 na 1 (33.3) 0
Sao Paulo, Brazil [37] 118 118 9 52 57 3 (2.5) 115 (97.5) 3 (2.5) 3 (2.5) 5 (4.2) 5 (4.2) na 12 (10.2) na
Santo Andre, SP, Brazil [43] 48 48 2 na 17 13 (27.1) 35 (72.9) 2 (4.2) 3 (6.3) 0 2 (4.2) 9 (19) na na
Lima, Peru [45] 28 28 0 0 28 11 (39.3) 17 (60.7) na na na na na 11 (39.3) 17 (60.7)
Total 1042 1022 96 232 191 213 (20.8) 809 (79.2) 65 (46.4) 25 (17.9) 28 (20) 13 (9.3) 9 (6.4) 168 (36.9) 287 (63.1)
  1. MMR mismatch repair, MSI microsatellite instabily, MSI-H MSI-high, MSS microsatellite stable; na not applied, SD standard deviation, IHC immunohistochemistry
\